INmune Bio Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
INMB
- Share Price
-
$1.04
- (As of Friday Closing)
INmune Bio General Information
Description
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Contact Information
Website
www.inmunebio.comCorporate Office
- 225 Northeast Mizner Boulevard
- Suite 640
- Boca Raton, FL 33432
- United States
Corporate Office
- 225 Northeast Mizner Boulevard
- Suite 640
- Boca Raton, FL 33432
- United States
INmune Bio Stock Performance
As of 13-Nov-2026, INmune Bio’s stock price is $1.04. Its current market cap is $32.5M with 31M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.04 | $1.05 | $1.01 - $2.60 | $32.5M | 31M | 328K | -$0.60 |
INmune Bio Financials Summary
As of 30-Sep-2026, INmune Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 37,114 | 14,819 | 72,906 | 174,023 |
| Revenue | 0 | 50 | 14 | 155 |
| EBITDA | (16,419) | (45,849) | (41,293) | (27,730) |
| Net Income | (16,666) | (45,933) | (42,082) | (30,008) |
| Total Assets | 21,508 | 32,351 | 39,562 | 57,001 |
| Total Debt | 1,210 | 1,034 | 384 | 10,437 |
INmune Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
INmune Bio Comparisons
Industry
Financing
Details
INmune Bio Competitors (83)
One of INmune Bio’s 83 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Redx Pharma | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
INmune Bio Patents
INmune Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250321234-A1 | Method for detecting anti-drug antibodies against self-assembling trimeric biologics using an affinity capture elution-protein a/g assay | Pending | 16-Apr-2024 | ||
| AU-2025232756-A1 | Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization | Pending | 08-Mar-2024 | ||
| WO-2025189204-A2 | Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization | Pending | 08-Mar-2024 | ||
| WO-2025189204-A3 | Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization | Pending | 08-Mar-2024 | ||
| WO-2025189204-A8 | Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization | Pending | 08-Mar-2024 | A61K47/60 |
INmune Bio Signals
INmune Bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
INmune Bio FAQs
-
When was INmune Bio founded?
INmune Bio was founded in 2015.
-
Where is INmune Bio headquartered?
INmune Bio is headquartered in Boca Raton, FL.
-
What is the size of INmune Bio?
INmune Bio has 21 total employees.
-
What industry is INmune Bio in?
INmune Bio’s primary industry is Drug Discovery.
-
Is INmune Bio a private or public company?
INmune Bio is a Public company.
-
What is INmune Bio’s stock symbol?
The ticker symbol for INmune Bio is INMB.
-
What is the current stock price of INmune Bio?
As of 13-Nov-2026 the stock price of INmune Bio is $1.04.
-
What is the current market cap of INmune Bio?
The current market capitalization of INmune Bio is $32.5M.
-
Who are INmune Bio’s competitors?
Aura Biosciences, ImmunityBio, Redx Pharma, Adimab, and Immunocore Holdings are some of the 83 competitors of INmune Bio.
-
What is INmune Bio’s annual earnings per share (EPS)?
INmune Bio’s EPS for 12 months was -$0.60.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process